Stämm Recognized in Inaugural SOSV Deep Tech 100

From Argentina to Valais: biomanufacturing innovator gains global recognition ! Stämm, the biotechnology company pioneering next-generation biomanufacturing systems, has been named among the inaugural SOSV Deep Tech 100, a selection recognizing 100 trailblazing companies from over 800 ventures in the global SOSV portfolio.

Stämm specializes in the development of microfluidic systems for biomanufacturing, rethinking how biologics can be produced at scale. The company is developing decentralized, plug-and-play, continuous biomanufacturing platforms inspired by natural processes. Its goal is to make therapies more accessible, scalable, and sustainable, reducing structural complexities in production and facilitating their delivery to patients globally.

The inclusion of Stämm in the SOSV Deep Tech 100 reflects its progress in addressing challenges in biomanufacturing. SOSV, a global multi-stage venture capital firm, is known for identifying and supporting frontier technologies with long-term impact. This recognition places Stämm among a community of innovators advancing deep tech solutions across sectors.

BioArk as a platform for growth

In 2024, Stämm established a Research & Development hub at BioArk Monthey, one of Valais’ two technology sites dedicated to life sciences alongside BioArk Visp. This recent installation represents an important milestone in Stämm’s international expansion strategy and signals its commitment to advancing innovative biomanufacturing processes. By joining the BioArk community, Stämm benefits from an ecosystem designed to support the industrial translation of biotech research.

A shared vision for sustainable health

Recognition by SOSV aligns with Stämm’s mission. By developing technology that reduces the complexity of bioproduction and adopts distributed, modular systems, the company contributes to a vision of healthcare shaped by efficiency, resilience, and accessibility. Within BioArk’s environment, Stämm illustrates how international biotech players can anchor their global ambitions in Valais while reinforcing the region’s innovation landscape.

More about Stämm

More about SOSV

30 September 2025
Scroll to Top